{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:47:32Z","timestamp":1776858452954,"version":"3.51.2"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:00:00Z","timestamp":1771027200000},"content-version":"vor","delay-in-days":13,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jtct.2026.02.046","type":"journal-article","created":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T16:34:55Z","timestamp":1771086895000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypogammaglobulinemia at Leukapheresis Predicts Delayed Humoral Immune Reconstitution and Increased Risk of Infections After CD19 CAR-T for B-Cell Lymphoma"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-8031-6311","authenticated-orcid":false,"given":"Tatsuro","family":"Hirao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9256-609X","authenticated-orcid":false,"given":"Daisuke","family":"Kaji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mika","family":"Kuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otoya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyosuke","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosei","family":"Kageyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Taya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aya","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsuke","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4975-8225","authenticated-orcid":false,"given":"Yuki","family":"Asano-Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5952-5926","authenticated-orcid":false,"given":"Naoyuki","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Wake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jtct.2026.02.046_bib0001","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1182\/blood.2023020854","article-title":"Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001","volume":"143","author":"Abramson","year":"2024","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2026.02.046_bib0002","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.jtct.2026.02.046_bib0003","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.046_bib0004","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2026.02.046_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.046_bib0006","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtct.2024.01.073","article-title":"Clinical impact of cytokine release syndrome on prolonged hematotoxicity after chimeric antigen receptor T cell therapy: KyoTox A-score, a novel prediction model","volume":"30","author":"Nakamura","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2026.02.046_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.06.008","article-title":"Clonal hematopoiesis is associated with severe cytokine release syndrome in patients treated with chimeric antigen receptor T-Cell (CART) Therapy","volume":"30","author":"Goldsmith","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"22","key":"10.1016\/j.jtct.2026.02.046_bib0008","doi-asserted-by":"crossref","first-page":"5443","DOI":"10.3390\/cancers15225443","article-title":"Population-based external validation of the EASIX scores to predict CAR T-cell-related toxicities","volume":"15","author":"De Boer","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.046_bib0009","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy","volume":"9","author":"Zandaki","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.jtct.2026.02.046_bib0010","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/s41591-024-03212-2","article-title":"Tracking non-relapse mortality after CAR T cell therapy","volume":"30","author":"Blumenberg","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.046_bib0011","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"23","key":"10.1016\/j.jtct.2026.02.046_bib0012","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","article-title":"Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days","volume":"5","author":"Mikkilineni","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.02.046_bib0013","doi-asserted-by":"crossref","first-page":"ofaa121","DOI":"10.1093\/ofid\/ofaa121","article-title":"Infectious complications following CD19 chimeric antigen receptor T-cell therapy for children, adolescents, and young adults","volume":"7","author":"Vora","year":"2020","journal-title":"Open Forum Infect Dis"},{"issue":"2","key":"10.1016\/j.jtct.2026.02.046_bib0014","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41409-020-01027-6","article-title":"Kinetics of humoral deficiency in CART19-treated children and young adults with acute lymphoblastic leukaemia","volume":"56","author":"Dey\u00e0-Mart\u00ednez","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.02.046_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T \u2013 and a side order of IgG, to go? \u2013 Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"},{"issue":"24","key":"10.1016\/j.jtct.2026.02.046_bib0016","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell\u2013related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.046_bib0017","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2002-12-3837","article-title":"Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma","volume":"102","author":"Hamlin","year":"2003","journal-title":"Blood"},{"issue":"27","key":"10.1016\/j.jtct.2026.02.046_bib0018","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.02.046_bib0019","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1182\/bloodadvances.2022009019","article-title":"Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma","volume":"7","author":"Roddie","year":"2023","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.jtct.2026.02.046_bib0020","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2026.02.046_bib0021","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.046_bib0022","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/bjh.17673","article-title":"Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"195","author":"Topp","year":"2021","journal-title":"Br J Haematol"},{"issue":"10","key":"10.1016\/j.jtct.2026.02.046_bib0023","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.jtct.2024.07.018","article-title":"Best practice considerations by the american society of transplant and cellular therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2026.02.046_bib0024","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.845540","article-title":"Infectious complications in pediatric, adolescent and young adult patients undergoing CD19-CAR T cell therapy","volume":"12","author":"Maron","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.jtct.2026.02.046_bib0025","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/pbc.21264","article-title":"Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias","volume":"50","author":"Rao","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2026.02.046_bib0026","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/hon.947","article-title":"Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab","volume":"29","author":"Kurokawa","year":"2011","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2026.02.046_bib0027","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2026.02.046_bib0028","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/blood-2016-01-694356","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy","volume":"128","author":"Bhoj","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2026.02.046_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.03.005","article-title":"Pathogen-specific humoral immunity and infections in B cell maturation antigen-directed chimeric antigen receptor T cell therapy recipients with multiple myeloma","volume":"28","author":"Josyula","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"10297","key":"10.1016\/j.jtct.2026.02.046_bib0030","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"The Lancet"},{"issue":"11","key":"10.1016\/j.jtct.2026.02.046_bib0031","article-title":"Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies","volume":"6","author":"Walti","year":"2021","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtct.2026.02.046_bib0032","doi-asserted-by":"crossref","DOI":"10.1182\/bloodadvances.2025016291","article-title":"Comparative infection risk in CAR T vs bispecific antibodies in B cell lymphoma: a systematic review and meta-analysis","author":"van Besien","year":"2025","journal-title":"Blood Adv"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001491?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726001491?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T11:09:13Z","timestamp":1776856153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726001491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":32,"alternative-id":["S2666636726001491"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.046","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hypogammaglobulinemia at Leukapheresis Predicts Delayed Humoral Immune Reconstitution and Increased Risk of Infections After CD19 CAR-T for B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.02.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}